Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
- 1 September 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 106 (3), 492-501
- https://doi.org/10.1097/01.aog.0000175834.77215.2e
Abstract
To compare the efficacy of a new low-dose oral contraceptive pill (OCP) formulation with placebo in reducing symptoms of premenstrual dysphoric disorder. This multicenter, double-blind, randomized clinical trial consisted of 2 run-in and 3 treatment cycles with daily symptom charting; 450 women with symptoms of premenstrual dysphoric disorder were randomized to either placebo or an OCP formulation containing drospirenone 3 mg and ethinyl estradiol 20 microg. Hormones were administered for 24 days, followed by 4 days of inactive pills (24/4). Scores on the total Daily Record of Severity of Problems decreased by -37.49 in the drospirenone/ethinyl estradiol group and by -29.99 in the placebo group (adjusted mean difference -7.5, 95% confidence interval [CI] -11.2 to -3.8; P < .001 by rank analysis of covariance). Mood symptom scores were reduced by -19.2 and -15.3 in active-treatment and placebo groups, respectively (adjusted mean difference -3.9, 95% CI -5.84 to -2.01; P = .003); physical symptom scores were reduced by -10.7 and -8.6 in active-treatment and placebo groups, respectively (adjusted mean difference -2.1, 95% CI -3.3 to -0.95; P < .001); and behavioral symptom scores were reduced by -7.7 and -6.2 in active-treatment and placebo groups, respectively (adjusted mean difference -1.5, 95% CI -2.251 to -0.727; P < .001). Response, defined as a 50% decrease in daily symptom scores, occurred in 48% of the active-treatment group and 36% of the placebo group (relative risk 1.7, 95% CI 1.1 to 2.6; P = .015) and corresponds to a number-needed-to-treat of 8 patients. A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 mug improves symptoms associated with premenstrual dysphoric disorder. I.Keywords
This publication has 23 references indexed in Scilit:
- Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: A Double-Blind, Placebo-Controlled TrialPsychosomatic Medicine, 2004
- Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorderPublished by Ovid Technologies (Wolters Kluwer Health) ,2002
- Oral contraceptives and moodExpert Opinion on Pharmacotherapy, 2001
- Hormone withdrawal symptoms in oral contraceptive usersObstetrics & Gynecology, 2000
- Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual SyndromeNew England Journal of Medicine, 1998
- A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndromePsychoneuroendocrinology, 1995
- Fluoxetine in the Treatment of Premenstrual DysphoriaNew England Journal of Medicine, 1995
- Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparationsContraception, 1992
- Oral contraceptives and depression: Impact, prevalence and causeJournal of Adolescent Health Care, 1981
- Premenstrual tension syndrome: The development of research diagnostic criteria and new rating scalesActa Psychiatrica Scandinavica, 1980